成人の臀部皮膚弛緩改善におけるJuläine™の安全性と性能を評価するための前向き臨床試験。
成人の殿部皮膚弛緩を改善するためのポリ-L-乳酸 - Juläine™の安全性と性能を評価する前向き臨床試験。
This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.
Participants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.
The primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.
This multicenter trial will be conducted in Brazil.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is an pivotal, open-label, two-arm, randomized, parallel-group, prospective clinical investigation conducted in Brazil to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) administered as subcutaneous injections for the treatment skin laxity in the buttock (gluteal) region in adults.
A total of 100 participants will be randomized to either an immediate-treatment group or a delayed-treatment group (delayed-start control). Participants in the immediate-treatment group will receive Juläine™ subcutaneous injections in 2 or 3 sessions at Day 0, Day 30, and Day 60. During this initial control period, outcomes in the immediate-treatment group will be compared with those in the delayed-treatment group, which will not receive treatment. After the control period, participants in the delayed-treatment group will receive the same Juläine™ regimen at Day 240, Day 270, and Day 300. Each participant will remain in the study for up to 16 months, excluding screening.
The primary efficacy endpoint is improvement in buttock skin elasticity 6 months after the last injection defined as an increase in global skin elasticity measured by a cutometer, with assessments at screening/baseline and at the primary post-treatment timepoint. The mean change in global skin elasticity measured by cutometer and Global Aesthetic Improvement Scale (GAIS) will also be evaluated, comparing groups during the control period.
Safety will be monitored through the collection of adverse events (AEs) through 240 days after randomization, with comparisons between groups during the control period. Adverse events will also be evaluated through extended follow-up, including up to 180 days in the overall study population and up to 480 days in the immediate-treatment group.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 18 to 55 years;
- Body Mass Index (BMI) between 18.5 and 24.95 kg/m².
- Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.
- Women of childbearing potential must be willing to abide by the contraceptive requirements
- Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.
Exclusion Criteria:
- Pregnancy or breastfeeding, or planned pregnancy/lack of adequate contraception (through 8 weeks post-study);
- Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.
- Active infection, inflammation or lesions at or near the treatment site.
- Acute infection at screening;
- History of autoimmune disease;
- Immune deficiencies;
- History of hypertrophic scarring or keloid formation;
- History of thrombosis in the lower limbs.
- Previous surgical procedures involving the buttocks
- Previous treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
- Previous aesthetic procedures in the treatment area, including radiofrequency, ultrasound, cryotherapy, neurotoxin, laser or light treatment, or chemical peel, within six months before randomization.
- Previous topical or home therapy for cellulite in the treatment area within three months before randomization.
- Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy.
- Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).
- Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.
- Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.
- Use of other agents that inhibit collagen production.
- Known allergy or hypersensitivity to any component of the investigational product.
- History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.
- Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).
- Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.
- Presence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
- Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected >10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change >10%, may be included.
- Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:即時治療群
|
Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres. |
|
他の:遅延治療群(遅延開始対照)
|
Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of participants who achieve an improvement in gluteal skin elasticity
時間枠:Baseline and 240 days after randomization
|
Proportion of participants achieving a clinically significant reduction in gluteal skin laxity at Day 240 after randomization, whereby a clinically significant reduction ("response") is defined as a relative increase of at least 10% in the gross elasticity measured by cutometer at Day 240 compared to baseline. |
Baseline and 240 days after randomization
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean change in overall skin elasticity
時間枠:Baseline and Day 240 after randomization.
|
Mean change in global medial skin elasticity measured by cutometer 180 days after treatment completion. |
Baseline and Day 240 after randomization.
|
|
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator
時間枠:Baseline and Day 240 after randomization.
|
Proportion of participants with at least a 1-point improvement in GAIS as rated by the investigator at Day 240 after randomization. The GAIS scale values are:
Where 1 represents the best outcome and 5 represents the worst. |
Baseline and Day 240 after randomization.
|
|
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant
時間枠:Baseline and Day 240 after randomization.
|
Proportion of participants with at least a 1-point improvement in GAIS as rated by the participant at Day 240 after randomization The GAIS scale values are:
Where 1 represents the best outcome and 5 represents the worst. |
Baseline and Day 240 after randomization.
|
|
Proportion of adverse events (AEs)
時間枠:Occurring up to 240 days after the start of treatment, in both groups.
|
Proportion of adverse events (AEs) occurring up to 240 days after randomization. |
Occurring up to 240 days after the start of treatment, in both groups.
|
|
Incidence and severity of Adverse events in the first 30 days
時間枠:First 30 days after each Juläine™ administration, in all treated participants.
|
Incidence and severity of Adverse events in the first 30 days after each Juläine™ administration, in all treated participants. |
First 30 days after each Juläine™ administration, in all treated participants.
|
|
Incidence and severity of AEs up to 240 days.
時間枠:Up to 240 days after start of treatment in all treated participants.
|
Incidence and severity of AEs up to 240 days after start of treatment in all treated participants. |
Up to 240 days after start of treatment in all treated participants.
|
|
Incidence and severity of AEs up to 480 days
時間枠:Up to 480 days after start of treatment in the immediate-start group.
|
Incidence and severity of AEs up to 480 days after start of treatment in the immediate-start group. |
Up to 480 days after start of treatment in the immediate-start group.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- NB 15-TF-BZ-100-08F
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。